Send a textWhat clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective.They explore:The evolving payer evidence landscape in the USPreferences for clinical and economic evidence by US payersKey differences between the US and other global markets with regard to evidence, HEOR, and market accessOpportunities and challenges when launching new medicines/medical devices/diagnostics in the USInnovative perspectives on evidence planning and strategy for the US marketUS payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer surveyThis episode was first broadcast as a live webinar in October 2024. Learn more at: https://mtechaccess.co.uk/navigating-us-payer-evidence-needs/Explore more about launching in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related